Rigacci, Luigi
 Distribuzione geografica
Continente #
NA - Nord America 1.784
EU - Europa 1.219
AS - Asia 340
AF - Africa 7
SA - Sud America 1
Totale 3.351
Nazione #
US - Stati Uniti d'America 1.782
RU - Federazione Russa 530
PL - Polonia 194
IE - Irlanda 139
IT - Italia 139
SG - Singapore 105
SE - Svezia 94
HK - Hong Kong 85
CN - Cina 73
CH - Svizzera 41
IN - India 30
DE - Germania 29
JO - Giordania 26
FI - Finlandia 24
GB - Regno Unito 12
VN - Vietnam 8
TR - Turchia 7
CI - Costa d'Avorio 6
UA - Ucraina 4
KR - Corea 3
RO - Romania 3
AT - Austria 2
BE - Belgio 2
CA - Canada 2
DK - Danimarca 2
PT - Portogallo 2
BR - Brasile 1
FR - Francia 1
IR - Iran 1
MU - Mauritius 1
NL - Olanda 1
PH - Filippine 1
TH - Thailandia 1
Totale 3.351
Città #
Santa Clara 296
Fairfield 204
Warsaw 192
Ashburn 144
Chandler 141
Dublin 139
Seattle 123
Woodbridge 101
Cambridge 91
Houston 85
Singapore 73
Wilmington 72
Hong Kong 50
Ann Arbor 49
Bern 41
Lawrence 38
Altamura 37
Princeton 33
Florence 32
Beijing 25
Buffalo 25
Mumbai 25
Moscow 24
Kent 21
Boston 20
San Diego 17
Shanghai 17
Boardman 14
Medford 13
Bremen 10
Munich 10
Lappeenranta 9
Norwalk 9
Abidjan 6
Dong Ket 6
Los Angeles 6
Milan 5
Salerno 5
Sesto Fiorentino 5
Dearborn 4
Falls Church 4
Helsinki 4
Jacksonville 4
New York 4
Pune 4
Andover 3
Cerea 3
Guangzhou 3
Izmir 3
Latina 3
London 3
Olgiate Olona 3
Redwood City 3
Timisoara 3
Washington 3
Aversa 2
Brussels 2
Chengdu 2
Copenhagen 2
Fontebuona 2
Hounslow 2
Pralboino 2
Radomsko 2
Rome 2
Saint Petersburg 2
Seoul 2
Shenzhen 2
Sinalunga 2
Surrey 2
Vienna 2
Yubileyny 2
Angeles City 1
Aprilia 1
Bangkok 1
Central District 1
Council Bluffs 1
Dezhou 1
Fasano 1
Genova 1
Hillsboro 1
Incisa 1
Jinhua 1
Kilburn 1
Laurel 1
Lisbon 1
Lucca 1
Nagold 1
Nanjing 1
Oggiono 1
Old Bridge 1
Paceco 1
Palermo 1
Philadelphia 1
Phoenix 1
Quanzhou 1
Ravenna 1
Redmond 1
Romola 1
Rui'an 1
São Paulo 1
Totale 2.328
Nome #
Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience 237
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients 173
Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study 164
The ion channels and transporters gene expression profile indicates a shift in excitability and metabolisms during malignant progression of Follicular Lymphoma 156
Role of core needle biopsy in primary breast lymphoma 124
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 119
Focal spleen lesions in visceral leishmaniasis, a neglected manifestation of a neglected disease: report of three cases and systematic review of literature 117
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment 117
Diffusion-Weighted and Perfusion-Weighted MRI to Evaluate Therapeutic Response in Lymphoma: A Comparison with FDG-PET/CT 115
A gene expression-based model to predict metabolic response after two courses of ABVD in Hodgkin Lymphoma patients 114
Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. 112
CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL) 112
Romiplostim before splenectomy in a patient with aggressive non-Hodgkin lymphoma and poor response to platelet transfusions 111
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 109
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity 106
The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL) 103
Baseline metabolic tumor volume calculation using different SUV thresholding methods in Hodgkin lymphoma patients: Interobserver agreement and reproducibility across software platforms 103
Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma 101
Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen 100
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 97
Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. 91
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 90
CMV AND EBV REACTIVATION AFTER AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION WITH BEAM CONDITIONING REGIMEN FOR MULTIPLE SCLEROSIS AND LYMPHOMA: A RETROSPECTIVE SINGLE CENTER CASE-CONTROL STUDY 87
Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma 87
Treatment and prognosis of primary pulmonary lymphoma: a long-term follow-up study 84
Aggressive Disease Course of Multiple Myeloma with Concomitant ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report with an Unusual Presentation 83
Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients. 81
In vitro activity of folate antagonists against methotrexate-resistant CCRF-CEM human T-leukemia sublines and relationships with folate pathway gene expression profiles 68
Pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B cell lymphoma: preliminary results 66
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 62
In vitro activity of folate antagonists against methotrexate-resistant CCRF-CEM human T-leukemia sublines and relationships with folate pathway gene expression profiles 58
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 47
Totale 3.394
Categoria #
all - tutte 10.757
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.757


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020404 0 0 0 0 60 63 60 66 64 34 39 18
2020/2021378 23 47 7 29 18 32 26 42 33 71 28 22
2021/2022242 1 12 29 17 9 10 14 20 21 11 38 60
2022/2023662 47 120 36 45 37 105 80 43 84 7 11 47
2023/2024296 7 29 34 7 35 38 6 72 7 18 32 11
2024/20251.070 54 180 108 343 385 0 0 0 0 0 0 0
Totale 3.394